AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT100.56-1.89 (-1.84%) ▼|ACN240.28+1.16 (+0.49%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.63-5.93 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.64+5.30 (+1.66%) ▲|BA192.31+1.84 (+0.97%) ▲|BAC50.80+0.16 (+0.32%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.10+20.42 (+1.81%) ▲|BMY61.16-0.53 (-0.85%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B541.16+1.34 (+0.25%) ▲|C123.84+1.33 (+1.08%) ▲|CAT740.16+14.92 (+2.06%) ▲|CL93.42-1.13 (-1.19%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.49+4.93 (+2.44%) ▲|COP145.70-0.25 (-0.17%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.72-0.71 (-0.29%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.76+1.05 (+0.46%) ▲|DE636.56+4.36 (+0.69%) ▲|DHR234.02+9.78 (+4.36%) ▲|DIS111.82+0.15 (+0.13%) ▲|DUK120.69-0.64 (-0.53%) ▼|EMR163.13+2.67 (+1.66%) ▲|FDX298.18-0.58 (-0.19%) ▼|GD344.91+0.47 (+0.14%) ▲|GE295.84-4.04 (-1.35%) ▼|GEV926.39+36.06 (+4.05%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.10-0.99 (-1.28%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.50+19.69 (+2.23%) ▲|HD314.08-1.03 (-0.33%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.06+9.14 (+3.78%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.65-1.71 (-0.66%) ▼|JPM335.13-0.13 (-0.04%) ▼|KO92.68-0.82 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,272.20-11.46 (-0.89%) ▼|LMT551.97+3.26 (+0.59%) ▲|LOW196.55-0.73 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.50+2.08 (+0.33%) ▲|MCD246.22-0.30 (-0.12%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.69+3.32 (+1.94%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.89+1.59 (+1.07%) ▲|MS187.11+6.71 (+3.72%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.25-0.61 (-0.77%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.14+3.60 (+2.41%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.10-2.04 (-1.56%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.86-0.25 (-0.83%) ▼|PG156.89-2.43 (-1.53%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.47-2.43 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.29+6.92 (+1.01%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT100.56-1.89 (-1.84%) ▼|ACN240.28+1.16 (+0.49%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.63-5.93 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.64+5.30 (+1.66%) ▲|BA192.31+1.84 (+0.97%) ▲|BAC50.80+0.16 (+0.32%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.10+20.42 (+1.81%) ▲|BMY61.16-0.53 (-0.85%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B541.16+1.34 (+0.25%) ▲|C123.84+1.33 (+1.08%) ▲|CAT740.16+14.92 (+2.06%) ▲|CL93.42-1.13 (-1.19%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.49+4.93 (+2.44%) ▲|COP145.70-0.25 (-0.17%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.72-0.71 (-0.29%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.76+1.05 (+0.46%) ▲|DE636.56+4.36 (+0.69%) ▲|DHR234.02+9.78 (+4.36%) ▲|DIS111.82+0.15 (+0.13%) ▲|DUK120.69-0.64 (-0.53%) ▼|EMR163.13+2.67 (+1.66%) ▲|FDX298.18-0.58 (-0.19%) ▼|GD344.91+0.47 (+0.14%) ▲|GE295.84-4.04 (-1.35%) ▼|GEV926.39+36.06 (+4.05%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.10-0.99 (-1.28%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.50+19.69 (+2.23%) ▲|HD314.08-1.03 (-0.33%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.06+9.14 (+3.78%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.65-1.71 (-0.66%) ▼|JPM335.13-0.13 (-0.04%) ▼|KO92.68-0.82 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,272.20-11.46 (-0.89%) ▼|LMT551.97+3.26 (+0.59%) ▲|LOW196.55-0.73 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.50+2.08 (+0.33%) ▲|MCD246.22-0.30 (-0.12%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.69+3.32 (+1.94%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.89+1.59 (+1.07%) ▲|MS187.11+6.71 (+3.72%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.25-0.61 (-0.77%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.14+3.60 (+2.41%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.10-2.04 (-1.56%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.86-0.25 (-0.83%) ▼|PG156.89-2.43 (-1.53%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.47-2.43 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.29+6.92 (+1.01%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
16.8 C
New York
Wednesday, October 21, 2026

Tag: exchange

newsFORsourcecompanycontentinformation1releasesmarket

SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important...

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SES AI Corporation (NYSE: SES) between January 29, 2025 and March 4, 2026, both dates inclusive (the “Class Period”), of the important June 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

Defiance ETFs Umumkan Penggantungan Sementara Dagangan Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc.

MIAMI, June 14, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, peneraju dalam dana dagangan bursa bertema dan berleveraj, hari ini mengumumkan bahawa dagangan saham Defiance Daily 2X Space ETF (Cboe BZX: SPCL) telah digantung buat sementara waktu oleh Cboe BZX Exchange, Inc. (“Bursa”).

Defiance ETFs 宣布 Defiance Daily 2X Space ETF (SPCL) 在 Cboe BZX Exchange, Inc. 暂停交易

迈阿密, June 14, 2026 (GLOBE NEWSWIRE) -- 主题型及杠杆型交易所交易基金领域的领军者 Defiance ETFs 今日宣布，Defiance Daily 2X Space ETF (Cboe BZX 交易所代码：SPCL) 份额的交易已被 Cboe BZX Exchange, Inc.（简称“交易所”）临时暂停。

Defiance ETFs 宣佈，Defiance Daily 2X Space ETF (SPCL) 暫時停止於 Cboe BZX Exchange, Inc. 進行交易

邁阿密, June 14, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs 作為主題與槓桿型交易所買賣基金 (ETF) 領導先鋒，今天宣佈 Defiance Daily 2X Space ETF (Cboe BZX: SPCL) 的股份已被 Cboe BZX Exchange, Inc.（「交易所」）暫時停止買賣。

ディファイアンスETFs、シーボーBZX取引所におけるディファイアンス・デイリー2XスペースETF (SPCL) の一時取引停止を発表

マイアミ発, June 14, 2026 (GLOBE NEWSWIRE) -- テーマ型およびレバレッジ型上場投資信託 (ETF) のリーダーであるディファイアンスETFs (Defiance ETFs) は本日、ディファイアンス・デイリー2XスペースETF (Defiance Daily 2X Space ETF) (Cboe BZX: SPCL) の取引が、シーボーBZX取引所 (Cboe BZX Exchange, Inc.) (以下「同取引所」) により一時停止されたことを発表した。

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

TAIWAN DESIGN POWER Debuts at Busan Design Festival, Showcasing Taiwan’s Design Innovation and Creative Value

The "TAIWAN DESIGN POWER" Taiwan Pavilion, showcased at the Busan Design Festival in South Korea, brings together 25 design projects and 20 industry representatives, demonstrating...

Salomon Unfolds the Next Chapter of ROAD TO THE FUTURE in Shanghai

SHANGHAI, June 14, 2026 (GLOBE NEWSWIRE) -- French outdoor brand Salomon has officially unsealed the latest instalment of the ROAD TO THE FUTURE programme at the Anfu concept store in Shanghai, China. This event unveiled the full launch of the 2026 Road to the Future Design Competition. Guest designer Uma Wang joins eight emerging designers to debut exclusive collaborative footwear designs, coinciding with the public opening of the project’s in-store display and official launch of public voting phase. Salomon China brand ambassador Bai Jingting attended the opening event, uniting established designers, cross-industry professionals and industry medias to dissect the evolving trajectory of the emerging boundaries of outdoor and fashion industry. In the future, Salomon will continuously explore the boundaries of outdoor aesthetics through creativities.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

Gala Night of the 28th Shanghai International Film Festival Held in Shanghai

SHANGHAI, June 13, 2026 /PRNewswire/ -- The Gala Night of the 28th Shanghai International Film Festival (SIFF) was held in Shanghai today, bringing together...

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsExchange

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers